Issue Information
Vidal LL, et al. NS3 protease polymorphisms and genetic barrier to drug resistance of distinct HCV genotypes from worldwide treatment‐naive subjects. JVH, 2016, 23(11)
NS3 protease polymorphisms and genetic barrier to drug resistance of distinct hepatitis C virus genotypes from worldwide treatment‐naïve subjects
Pharmacokinetics, efficacy and safety of daclatasvir plus asunaprevir in dialysis patients with chronic hepatitis C
Sofosbuvir and ledipasvir improve patient‐reported outcomes in patients co‐infected with hepatitis C and human immunodeficiency virus
Hepatitis C viral dynamics during ribavirin priming differ according to prior treatment response and HCV type
Anti‐envelope antibody responses in individuals at high risk of hepatitis C virus who resist infection
Hepatitis C genotype distribution in patient and blood donor samples in South Africa for the period 2008–2012
Insulin resistance increases loss of antibody to hepatitis B surface antigen in nondiabetic healthy adults
Implementation of an in‐house quantitative real‐time polymerase chain reaction method for Hepatitis B virus quantification in West African countries
Baseline HBsAg and HBcrAg titres allow peginterferon‐based ‘precision medicine’ in HBeAg‐negative chronic hepatitis B patients
The gamma‐glutamyl transpeptidase‐to‐platelet ratio predicts liver fibrosis and cirrhosis in HBeAg‐positive chronic HBV infection patients with high HBV DNA and normal or mildly elevated alanine transaminase levels in China
Clinical characteristics and long‐term outcome of acute kidney injury in patients with HBV‐related acute‐on‐chronic liver failure
Evidence of Hepatitis E virus breaking through the blood–brain barrier and replicating in the central nervous system
Hospitalization and mortality due to hepatitis A in Taiwan